RxDoctor Payments Data

Renee Walker, DO

Pediatric Otolaryngology · Joplin, MONPI 1417949488

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,552 of the $8,168 with a category attached, or 68.0%. Novartis accounts for 69.9% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $6,625 and has fallen 92.8% since, to $474 in 2025. Among pediatric otolaryngology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,168in general payments, 2019–2025

Across 97 payments — averaging $84.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6K
  • Intersect ENT, Inc.$476
  • Regeneron Healthcare Solutions, Inc.$403
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$229
  • Acclarent, Inc$219
  • Sanofi$196
  • plus $938 from 18 others

What the payments were for

  • Consulting fees$751%
  • Speaking & faculty fees$5,55268%
  • Food & beverage$2,37229%
  • Education$991%
  • Other$701%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,168 in reported general payments places this provider in the 95th percentile of 20 pediatric otolaryngology providers in Missouri.

See all pediatric otolaryngology providers in Missouri

Medicare billing

Part B allowed, 2024
$55,866
Medicare patients
266
Services billed
2,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab11$40,577
XolairOmalizumab11$35,466
SymbicortBudesonide/Formoterol Fumarate12$6,815
Epinephrine31$4,884
Ipratropium Bromide78$1,630
Fluocinolone Acetonide Oil39$1,330
Ofloxacin26$613
Azelastine Hcl30$347
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$295
Omeprazole15$291
Betamethasone Dipropionate11$271
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$173
Mupirocin12$78
Methylprednisolone20$77
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala$12$40,57711 claims
AstraZenecaSymbicort$187$6,81512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 pediatric otolaryngology providers in Missouri.

Other pediatric otolaryngology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →